Impact of Iron Oxide on Anaerobic Digestion of Frass in Biogas and Methanogenic Archaeal Communities' Analysis.

With the increasing prominence of the global energy problem, socioeconomic activities have been seriously affected. Biofuels, as a renewable source of energy, are of great significance in promoting sustainable development. In this study, batch anaerobic digestion (AD) of frass (swine manure after bioconversion by black soldier fly larvae) and co-digestion with corn straw after the addition of iron oxide (Fe3O4) nanoparticles is investigated, as well as the start-up period without inoculation. The biochemical methane potential of pure frass was obtained using blank 1 group and after the addition of various sizes of Fe3O4 nanoparticles for 30 days period, and similarly, the digestion of frass with straw (blank 2) and after the addition of various sizes of Fe3O4 nanoparticles for 61 days period. The results showed that the average gas production was 209.43 mL/gVS, 197.68 mL/gVS, 151.85 mL/gVS, and 238.15 mL/gVS for the blank, ~176 nm, ~164 nm, and ~184 nm, respectively. The average gas production of frass with straw (blank 2) was 261.64 mL/gVS, 259.62 mL/gVS, 241.51 mL/gVS, and 285.98 mL/gVS for blank 2, ~176 nm, ~164 nm, and ~184 nm, respectively. Meanwhile, the accumulated methane production of the ~184 nm group was 2312.98 mL and 10,952.96 mL, respectively, which significantly increased the biogas production compared to the other groups. The methanogenic results of the frass (30 days) indicated that Methanocorpusculum, Methanosarcina, and Methanomassiliicoccus are the important methanogenic species in the AD reactor, while the microbial diversity of the ~184 nm group was optimal, which may be the reason for the high gas production of ~184 nm.

Pharmacological Inhibition of TXNRD1 by a Small Molecule Flavonoid Butein Overcomes Cisplatin Resistance in Lung Cancer Cells.

Mammalian cytosolic selenoprotein thioredoxin reductase (TXNRD1) is crucial for maintaining the reduced state of cellular thioredoxin 1 (TXN1) and is commonly up-regulated in cancer cells. TXNRD1 has been identified as an effective target in cancer chemotherapy. Discovering novel TXNRD1 inhibitors and elucidating the cellular effects of TXNRD1 inhibition are valuable for developing targeted therapies based on redox regulation strategies. In this study, we demonstrated that butein, a plant-derived small molecule flavonoid, is a novel TXNRD1 inhibitor. We found that butein irreversibly inhibited recombinant TXNRD1 activity in a time-dependent manner. Using TXNRD1 mutant variants and LC-MS, we identified that butein modifies the catalytic cysteine (Cys) residues of TXNRD1. In cellular contexts, butein promoted the accumulation of reactive oxygen species (ROS) and exhibited cytotoxic effects in HeLa cells. Notably, we found that pharmacological inhibition of TXNRD1 by butein overcame the cisplatin resistance of A549 cisplatin-resistant cells, accompanied by increased cellular ROS levels and enhanced expression of p53. Taken together, the results of this study demonstrate that butein is an effective small molecule inhibitor of TXNRD1, highlighting the therapeutic potential of inhibiting TXNRD1 in platinum-resistant cancer cells.